MedicalCV Announces Completion of First U.S. Clinical Case Using AtriLaze(TM) Surgical Ablation System in Open-Heart Surgery The Laser System Precisely Replicated Maze Lesions MINNEAPOLIS, Jan. 24 /PRNewswire-FirstCall/ -- MedicalCV, Inc. (OTC:MDCV) (BULLETIN BOARD: MDCV) , http://www.medcvinc.com/ , a cardiovascular surgery device manufacturer, focusing on surgical needs surrounding atrial fibrillation, announced today the completion of the first U.S. human clinical case using the AtriLaze(TM) Surgical Ablation System. The diode laser system allows the cardiovascular surgeon to deliver laser energy to atrial tissue creating exact and complete lines of cardiac tissue ablation. Dr. Carmelo Otero, Cardiothoracic and Vascular Surgeon, performed the first U.S. clinical case at Christus Santa Rosa Hospital in San Antonio, Texas. The 53 year old, female patient presented with paroxysmal atrial fibrillation (A-Fib), mitral and tricuspid valve and coronary artery disease. The AtriLaze(TM) surgical ablation procedure was performed as a concomitant procedure with mitral valve replacement and tricuspid valve repair. Use of the AtriLaze(TM) system added a minimal amount of time to the overall surgical procedure. "The AtriLaze(TM) system performed well, allowing me to easily and precisely replicate Maze lesions," said Dr. Otero. "The laser technology provides me the capability to safely and quickly create an array of cardiac lesions that enabled today's successful clinical case. The AtriLaze(TM) system facilitates a simple, reproducible technique that I believe will be very effective in concomitant cardiac surgical procedures and potentially lends itself to minimally invasive and robotic surgical treatments of A-Fib," commented Dr. Otero. Marc P. Flores, President and Chief Executive Officer of MedicalCV, Inc. commented, "We are pleased to enter the U.S. market with this innovative technology for surgical cardiac tissue ablation. The atrial fibrillation market is in a state of chaos looking for an 'ideal' technological solution to provide a minimally invasive surgical option that mirrors outcomes of the 'gold standard' surgical Maze procedure. This successful surgery represents a further milestone in the Company's goal of providing a better treatment solution for ablating cardiac tissue." MedicalCV, Inc. acquired rights to the AtriLaze(TM) Surgical Ablation System in September 2003 and received FDA 510(k) clearance on November 30, 2004. The Company is currently marketing the AtriLaze(TM) system for clinical use and is focusing its resources on the minimally invasive treatment of A-Fib as a stand-alone procedure. "The laser's physical properties are a specific balance of absorption and transmission through atrial tissue that optimizes overall photocoagulation," said Adam L. Berman, Vice President, Research and Development. "Through our continued development efforts, we believe the delivery of light energy through low-profile fiberoptic elements has the potential to enable closed-chest, beating heart procedures for cardiac tissue ablation." About MedicalCV, Inc. MedicalCV, a cardiovascular surgery device manufacturer, focuses on the design, development and commercialization of new, improved and enhanced technologies, products, methods and techniques to treat cardiovascular disorders and disease, including products targeting the treatment of atrial fibrillation. Historically, MedicalCV developed and marketed Omnicarbon(R) mechanical heart valves and its proprietary pyrolytic carbon processes. The Company acknowledges their continued maintenance of the mechanical heart valve business, supporting their customers and distributors during the divestiture process. The Company also continues to concentrate it resources on the A-Fib market. The Company's securities are traded on the OTC Bulletin Board under the symbol "MDCV." For further information on MedicalCV, Inc., please visit http://www.medcvinc.com/ . You may register to receive MedicalCV's future press releases and to be added to the Company's distribution list by visiting: http://www.roiny.com/form.php . This release contains certain forward-looking statements of expected future developments, as defined in the Private Securities Litigation Reform Act of 1995. The forward-looking statements in this release refer to our expectations regarding disposition of our heart valve business, operating improvements, development of atrial fibrillation product and minimally invasive treatment of atrial fibrillation. These forward-looking statements reflect management's expectations and are based on currently available data; however, actual results are subject to future risks and uncertainties, which could materially affect actual performance. Risks and uncertainties that could affect such performance include, but are not limited to, the following: the Company's ability to fund significant capital needs; market acceptance in the U.S. of the Company's cardiovascular products; acceptance, efficaciousness and safety of minimally invasive techniques for the reduction of atrial fibrillation through ablation; potential reductions in pricing by competitors; the costs of licensing and acquiring new products and technologies; the time and costs involved in obtaining regulatory clearance for cardiovascular products; competing technological and market developments; physician acceptance of the Company's cardiovascular products; dependence upon governmental reimbursements and third party supplies; and the strength of the market for cardiovascular products. For more detailed information about these risks and uncertainties, please review the Company's Annual Report on Form 10- KSB for the fiscal year ended April 30, 2004, and the Form 8-K filed January 6, 2005. These events and uncertainties are difficult or impossible to predict accurately and many are beyond the Company's control. The Company assumes no obligation to publicly release the results of any revisions that may be made to any forward-looking statements to reflect events or uncertainties after the date of such statements or to reflect the occurrence of anticipated or unanticipated events. DATASOURCE: MedicalCV, Inc. CONTACT: John H. Jungbauer, Vice President, Finance and CFO of MedicalCV, Inc., +1-651-452-3000, , or Investor Relations, Robert Giordano, President, +1-212-495-0200, ext. 10, , or Sarah Shepard, Vice President, +1-212-495-0200, ext. 17, , both of ROI Group Associates, Inc. Web site: http://www.medcvinc.com/

Copyright